See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/324732168
Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles
Article in Artificial Cells · April 2018
DOI: 10.1080/21691401.2018.1464460
CITATIONS
0
READS
31 5 authors, including:
Some of the authors of this publication are also working on these related projects:
Uses of modified surface PLGA nanoparticles for antigene delivery through Nasal admistrationView project
Target drug delivery of cisplatinView project Jafar Mosafer
Torbat Heydariyeh University of Medical Science 16PUBLICATIONS 89CITATIONS
SEE PROFILE
Ali Badiee
Mashhad University of Medical Sciences 54PUBLICATIONS 794CITATIONS
SEE PROFILE
Mohsen Tafaghodi
Mashhad University of Medical Sciences 73PUBLICATIONS 936CITATIONS
SEE PROFILE
All content following this page was uploaded by Jafar Mosafer on 02 May 2018.
The user has requested enhancement of the downloaded file.
Immunization against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles
Jafar Mosafera,b, Ali Badieeb,c, Zahra Mohammadaminic, Alireza Komeilinezhadc and Mohsen Tafaghodib,c
aResearch Center of Advanced Technologies in Medicine, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran;
bNanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran;cSchool of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
ABSTRACT
Chitosan-coated ISCOMATRIX nanoparticles co-administrated with PR8 influenza virus were successfully developed via a lipid film hydration method to evaluate their in vivo immuniadjuvant potential in immunization against influenza. The prepared ISCOMATRIX (ISC) and chitosan-coated ISCOMATRIX (ISC-CIT) showed a particle size of 171 and 233 nm with a zeta potential of–9.47 andþ5.65, respect- ively. Furthermore, ISC-CIT formulations were co-administered with PR8 antigen (PR8-ISC-CIT) and their immunogenicity was investigated after intranasal and intramuscular immunization of BALBc/mice. The PR8-ISC formulation elicited more IFN-cafter intranasal or intramuscular administration compared with PR8-ISC-CIT formulation. In contrast, although PR8-ISC-CIT formulation administered by intranasal route secreted more IFN-c, it significantly decreased the IgG2a/IgG1 ratio and a less immune response was induced. Altogether, the ISC-adjuvanted influenza PR8 antigen could be considered as a powerful intra- muscular antigen delivery system for producing a variety of prophylactic and therapeutic vaccines.
ARTICLE HISTORY Received 17 December 2017 Revised 8 April 2018 Accepted 10 April 2018
KEYWORDS Immune response;
ISCOMATRIX; PR8 influenza virus; chitosan-coated ISCOMATRIX; nasal immunization
Introduction
During the past 30 years, enormous efforts have been per- formed for development of new adjuvants to be able to induce both humoral and cellular immune responses, particu- larly those with critical criteria including safety, immunogen- icity and clinical efficacy for human vaccines. Natural and synthetic polymers are also utilized to get nanoparticles car- rier systems for development of nasal mucosal antibodies [1].
For the first time, Morein et al. [2] in 1984 described the immunostimulating complex or “iscom”. Iscoms are usually caged-like structures that composed of phospholipid, choles- terol and saponin with mean diameter of40 nm [2–5]. Over the past 20 years, many progresses on development of human vaccines based on ISCOM adjuvant technology have been achieved (i.e. usually referred to as ISCOMVR, a registered trademark of ISCOTEC AB, a CSL Limited company, Sweden) [6]. ISCOMTM-based vaccines have the requisite characteristics to be used as a novel prophylactic and therapeutic agents to induce strong cellular immune response and/or antibody response, including CTL (CD8þT-cell) responses. They showed to be safe, highly immunogenic and efficacious that induced broad immune responses in human clinical trials resulted in 10- to 100-fold lower doses of antigen than is required with most of adjuvants, including aluminium [7]. It has been also shown that ISCOMTM-based vaccines are potent inducers of IgG2a antibody responses in mice resulted in a Th1-type immune response. Th1 immune response is gener- ally considered as a critical factor for producing a variety of
prophylactic and therapeutic vaccines, especially those are to prevent or treat viral infections and intracellular pathogens [8,9]. Although ISCOMTM-based vaccines consist of saponin as an adjuvant; however, ideal CTL induction is reached when antigen is also physically incorporated into their structures.
The rationale behind this is that the ISCOMTM-based vaccines have a particulate nature by which more efficiently taken up by immune cells such as antigen-presenting cells (APCs) or dendritic cells. Furthermore, the antigen is rapidly processed and presented to CD8þT-cells [6,10,11]. Antibody induction has been proved after immunization with ISCOMTM-based vaccines containing influenza virus antigens [12,13]. Also, antigen-specific proliferative T-cell responses have been reported in a variety of animal species immunized with an ISCOMTM-based vaccine formulation with influenza virus anti- gens [14]. In addition, it has been shown that ISCOMTM-based vaccines that were physically associated with influenza virus antigens could prime T cells and result in proliferation of these cells and cytokine secretion (IL-4 and IFN-c) [15]. Also, immunological outcomes clearly indicated significant improvement in humoral as well as cellular immune responses after pulmonary immunization against mycobacter- ium tuberculosis with Antigen 85 complex (Ag85)-loaded ISCOMs in mice [16]. ISCOMTM-based vaccines were tradition- ally prepared with incorporation of viral membrane proteins with a hydrophobic nature [17,18]. However, incorporation of hydrophilic antigens into the ISCOM structures was not suc- cessful [3]. This defect is mainly rooted from difficulty in 2
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118
CONTACTMohsen Tafaghodi [email protected] Nanotechnology Research Center, Mashhad University of Medical Sciences, P.O. Box 9196773117, Mashhad, Iran
ß2018 Informa UK Limited, trading as Taylor & Francis Group https://doi.org/10.1080/21691401.2018.1464460
manufacturing procedures. To overcome this limitation, ISCOMATRIX adjuvant (also called ISCOMATRIXTM, a trademark of ISCOTEC AB) was introduced. ISCOMATRIX adjuvants are also usually cage-like structures consisting of phospholipid, cholesterol and saponin, but without the inclusion of antigen.
These could be simply prepared by admixing the antigens with pre-formed ISCOMATRIXTM adjuvants [11]. One of the most important physical properties of the ISCOMATRIX adju- vants is their negatively charged surface, help them to associ- ate with positively charged materials such as chitosan.
Chitosan is a biocompatible and biodegradable cationic polymer derivatized from naturally occurring chitin, is com- posed of randomly distributed N-acetylglucosamine and b- (1,4)-linked glucosamine residues [19,20]. Numerous studies have established that chitosan is a penetration enhancer polymer for large hydrophilic compounds across the mucosal surfaces that not only increase the local therapeutic activity, but also increase the systemic availability of the drugs by increasing the residence time at the site of application [21,22]. The proposed mechanism is opening of intracellular tight junctions. Therefore, in this study, chitosan was used to 1 – act as a penetration enhancer and increase the trans- mucosal drug delivery; 2– physically link the ISCOMATRIX to negatively charged antigens; and 3– act as an adjuvant [23].
Nasal influenza immunization has distinct features compared with intramuscular vaccines, providing protection at the path- ogen’s entry site, higher levels of mucosal antibodies, cross- protection and needle-free application [1]. Human influenza A/Puerto Rico/8//1934 (H1N1) virus (PR8) was the most com- mon cause of human influenza at 2009 that is a subtype of influenza A virus [24,25]. Therefore, the PR8 antigen was mixed with ISCOMATRIX structures to evaluate the in vivo immunoadjuvant potential of these promising adjuvants.
Materials and methods Materials
Low molecular weight chitosan (deacetylation degree: 95%, intrinsic viscosity (1% solution: 11 cP) was donated by Primex (Siglufjordur, Iceland). IgG1 and IgG2a secondary antibodies were obtained from Zymed Inc. (South San Francisco, CA, USA). Coating and detection mAb antibodies for IFN-cand IL- 4 as well as streptavidin-HRP were obtained from Mabtech (Nacka Strand, Sweden). Concanavalin A was obtained from Sigma Aldrich (St. Louis, MO, USA). Fetal calf sera (FCS), RPMI1640 culture medium and penicillin–streptomycin solu- tion were purchased from Sigma Aldrich (St. Louis, MO, USA).
BALB/c mice and PR8 antigen were purchased from the Pasteur Institute of Iran. Mice were treated based on the guidelines of the Institutional Ethical Committee of Mashhad University of Medical Sciences.
Preparation of chitosan-coated ISCOMATRIX NPs
A lipid film hydration method was used to prepare the ISCOMATRIX (ISC) formulation [26]. The 2:2:1 (w/w/w) ratios of the EPC (Egg phosphatidylcholine) lipid: Quil-A saponin:
cholesterol were used. Firstly, 8 mg EPC and 4 mg cholesterol
were dissolved in chloroform, followed by the removal of chloroform under reduced pressure by a rotary evaporator (Hettich, Germany). Next, a mixture of tert-butanol and sucrose solution (100 mg/ml) was added to the dried lipid film (4 ml, v/v 1:1) and stirred for 5 min. The resulting lipid phase was flash-frozen on dry ice and then freeze-dried over- night at –60C (Lyph-Lock 12; Labconco Corp, Kansas City, MO, USA). To hydrate the solid matrices, a PBS solution (0.01 M, pH 7.4) of Quil A (8 mg/4 ml) was poured into the lipid phase and was subsequently subjected to short bath sonication for 10 min to facilitate the dispersion. Finally, the ISCOMATRIX dispersion was extruded through the polycar- bonate membranes with pore diameters between 100 and 400 nm (Avestin, Ottawa, Canada). The total lipid concentra- tion in the obtained formulation was 3 mg/ml.
In the next step, Chitosan-coated ISC (ISC-CIT) formulation was prepared by physical interaction between chitosan and ISC formulation [27,28]. One part (w) of ISC was simply mixed with two parts (w) of chitosan. Each component was dis- solved in phosphate buffer (PB, 8 mM, pH 6). Finally, PR8 anti- gen was added to the ISC-CIT formulation and simply mixed to prepare the PR8-ISC-CIT formulation. The PB dispersion of ISC-CIT formulations showed a pH of 6.2 that had a good col- loidal stability for two weeks at 2–8C in PB solution.
Therefore, all of ISCOMATRIX formulations were prepared in PB and stored at 2–8C until use.
Particle size distribution and morphology
Dynamic light scattering analysis (NANO-ZS, Malvern, UK) and transmission electron microscopy (Philips CM120; Philips Electron Optics, Holland) were used to determine the particle size distribution as well as the morphological of ISC nanoparticles.
In vivovaccination protocol
The in vivo evaluation of immunoadjuvant potential of pre- pared ISCOMATRIX formulations was investigated in male BALB/c mice. Eight groups were immunized by intramuscular (Im) or intranasal (In) routes with: 1: PBS solution as a nega- tive control (only subcutaneously injection), 2 and 3: PR8 anti- gen (15mg/mouse), 4 and 5: PR8-ISC formulation (15mg PR8 antigenþ25mg ISC/mouse), 6 and 7: PR8-ISC-CIT formulation (15mg PR8 antigenþ25mg ISCþ20mg chitosan/mouse) and 8 and 9: Blank ISC formulation (25mg ISC/mouse). Mice (6 per group) were injected three times in two-week intervals with these formulations. For nasal immunization, an intraperitoneal injection of ketamine and xylazine (100 and 10mg/g body weight, respectively) were used to anesthetize the mice and a total volume of 5ml of each formulation was administered into the two separated nostrils. For Im immunization, a total volume of 100ml of each formulation was administered.
In vitrocytokine production
An ELISA method was used to detect the levels of IFN-c and IL-4 produced by spleen cells. Ten days after the last booster 119
120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177
178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236
2 J. MOSAFER ET AL.
injection, 3 mice in each group were sacrificed and the spleens were removed, aseptically. To obtain a single-cell sus- pension, the spleen tissues were homogenized and then the mononuclear cells were removed using ammonium chloride [29]. Next, the washed splenocytes were resuspended in RPMI 1640 culture medium and seeded in 96-well plates at a dens- ity of 2105 cells/well. Then, the spleen cells were stimu- lated with either culture medium alone as negative control, PR8 antigen (10mg/ml), or Concanavaline A (Con A) as posi- tive control and incubated at 37C for 72 h. After that, the concentration of IL-4 and IFN-c were determined in the supernatants using ELISA technique based on the man- ufacturer’s instructions (Mabtech, Nacka, Sweden).
Antibody isotype assay
Ten days after the last booster injection, the mice blood sam- ples were obtained by heart puncture and retro orbital bleed- ing. The blood was allowed to coagulate at 4C and then the serum was collected by centrifuging for 10 min at 14,000 rpm.
The serum samples were and kept at20C [30]. The sera of vaccinated BALB/c mice were used to titrate IgG1 and IgG2a antibodies using an ELISA technique [31]. Briefly, 96-well plates were coated with 50ll (10mg/ml in bicarbonate buffer, pH 9.6) of PR8 antigen and kept overnight at 4C. After washing the plates, they were blocked with 300ml of 2.5%
BSA in PBS-Tween per well for 1 h at 37C. Different dilutions of serum were added to the plates for 75 min at 37C. After washing with PBS-Tween solution, plates were treated with IgG1 and IgG2a secondary antibodies based on the man- ufacturer’s instructions (Zymed Inc., South San Francisco, CA, USA). Optical density was measured by using a microplate reader (StatFaxVR 4200 microplate reader, NEOGENVR Corporation, USA) at 450 nm, with a reference wavelength of 630 nm.
Statistical analysis
Statistical analysis was performed using the version 6 of the GraphPad Prism (La Jolla, CA, USA). The data were analyzed
by a Tukey’s multiple comparison tests and a one-way ana- lysis of variance (ANOVA).
Results
Characterization of ISCOMATRIX formulations
In this study, ISCOMATRIX nanoparticles were prepared by a lipid film hydration method. The mean diameter of ISC for- mulation was 171.0 nm, as measured by DLS method (Figure 1(A)). The morphology of ISC NPs was depicted by TEM (Figure 1(B)). Coating of ISC NPs with chitosan significantly increased the particle size to 233.9 nm. Chitosan has a positive charge, thus resulting in higher zeta potential for the chitosan-coated ISC formulation compared to that of ISC alone. The obtained results are summarized inTable 1.
Cytokine assay
Splenocytes of mice immunized with different formulations were cultured. The concentration of IL-4 and IFN-c in the supernatant of cell cultures were determined by an ELISA method (Figure 2(A,B)). The results show that a more signifi- cant IFN-c response was induced following In administration of PR8-ISC formulations as compared with Im delivery of these formulations (p<.001). Also, a significant reduction of IFN-c concentration was observed when the PR8-ISC formulations were coated with CIT. The difference between IFN-cconcentra- tions induced by PR8-ISC-CIT formulation after nasal adminis- tration was more significant than Im injection. Altogether, ISCOMATRIX NPs as efficient immunoadjuvant could signifi- cantly increase the IFN-cresponse to the PR8 whole virus after In (p<.001) and Im administration (p<.001). Additionally, no 237
238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295
296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354
Figure 1. Particle size distribution and morphology and of ISC nanoparticles. (A) and (B) show the particle size and morphology of ISC nanoparticles using DLS and TEM analysis, respectively.
Table 1. Particle size, zeta potential and PDI of ISC formulation.
Formulations Method Particle size (nm)a PDI Zeta potentials (mV)
ISC DLS 171.0 0.23 9.47
TEM 64 – –
ISC-CIT DLS 233.9 0.36 þ5.65
aIs based on z-average results.
significant secretion of IL-4 was observed after immunization with these formulations.
Antibody response
In this study, the adjuvanticity of ISCOMATRIX NPs was inves- tigated by immunization of BALB/c mice [30]. The sera of vac- cinated BALB/c mice were used to titrate IGG1 and IgG2a antibodies using an ELISA technique [31]. ISCOMATRIX NPs could significantly increase both IgG1 and IgG2a antibody responses against PR8 whole virus after In and Im administra- tion (Figure 3(A,B)). Generally, no significant difference was observed between anti-PR8 IgG antibody titres of CIT-coated formulations and non-coated ones after In or Im administra- tion. The results also show that after Im administration, the IgG2a antibody titres are significantly higher than In adminis- tration, both after administration of PR8-ISC and PR8-ISC-CIT formulations (p<.001) (Figure 3(B)). Also, the IgG2a/IgG1 ratio was significantly higher in intramuscularly administered PR8-ISC and PR8-ISC-CIT formulations to those induced with intranasally delivered formulations (p<.001) (Figure 3(C)).
Discussion
Although aluminium salts are used in almost of the currently adjuvanted human vaccines, they usually induce a Th2 anti- body dominated response. Accordingly, they are not suitable adjuvants for vaccination against intracellular pathogens, chronic infections or cancers. To overcome this limitation, ISCOM and ISCOMATRIX adjuvants have shown good poten- tials [6,7]. ISCOMATRIX-adjuvanted vaccines are simply pre- pared by admixing the antigen with preformed ISCOMATRIX nanoparticles. Sj€olander et al. [32] showed that a CTL
response as well as strong mucosal and systemic immune responses was induced when PR8 antigen was co-adminis- tered with ISCOM formulations and delivered by the In route in BALBc/mice.
In this study, it has been shown that ISCOMATRIX NPs as efficient immunoadjuvant could significantly increase the IFN- c response to the PR8 whole virus, after both In (p<.001) and Im administration (p<.001). Helgeby et al. [33,34] incor- porated both the cholera toxin A1 (CTA1)-DD and PR8 influ- enza virus into the ISCOM and demonstrated that the immunogenicity of PR8 virus is significantly augmented after In immunization of BALBc/mice when compared with PR8 virus alone.
Both ISCOMATRIX and PR8 are negatively charged. With a hypothesis that connection between antigen and ISCOMATRIX could increase the potential of co-delivery of the both particles to the same APC or macrophage and increase the immune responses, ISCOMATRIX NPs were coated with chitosan as a cationic polymer. It is supposed that this cat- ionic coat could attach to the PR8 and help to co-delivery.
However, after co-administration of chitosan coated ISCOMATRIX NPs with PR8 virus (PR8-ISC-CIT), the IFN-c con- centration was less than PR8-ISC group. However, the nega- tive results (p<.01) could be attributed to the agglomeration of chitosan-coated PR8-ISC (PR8-ISC-CIT) and lower uptake of this formulation by M cells and APCs. After nasal administra- tion, the difference between IFN-c concentrations induced by these two formulations was more significant (p<.001) than im injection (p<.01). After nasal administrations, formulations should first pass through or be uptaken by epithelial, and mainly microfold cells. The possible aggregation of chitosan- coated PR8-ISC (PR8-ISC-CIT) could adversely affect this step and result in lower uptake and lower immune responses. But after Im injection, because of the absence of this epithelial 355
356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413
414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472
Figure 2. BALB/c mice were injected with different formulations. Splenocyets were cultured 10 days after the last booster injection and stimulatedin vitrowith either PR8 antigen (10mg/ml), Con A as positive control and culture medium alone as negative control incubated for 72 h. ELISA technique was used to determine the concentration of IFN-cand IL-4 in supernatants. Significant differences between the PR8-ISC (Im) and PR8-ISC-CIT (Im) groups with the PR8 (Im) group marked as(p<.001). Significant differences between PR8-ISC-CIT (Im) and PR8-ISC-CIT (In) groups labelled with #(p<0.05). Data expressed as mean ± SD (n¼6).
4 J. MOSAFER ET AL.
barrier, both PR8-ISC-CIT and PR8-ISC formulations are simi- larly uptaken by immune cells, and no significant differences were observed between the immune responses induced by PR8-ISC and PR8-ISC-CIT formulations.
It has been also shown that influenza antigens are potent inducers of IgG2a antibody responses in mice and resulted in a Th1-type immune response that is generally considered as a critical factor for producing a variety of prophylactic and therapeutic vaccines, especially those are to prevent or treat viral infections and intracellular pathogens [8,9]. Therefore, it is beneficial to elicit a higher ratio of IgG2a/IgG1 antibody titres for immunization against influenza virus. The ratio of IgG2a/IgG1 antibody titres is usually used as an indicator of Th profile [35]. When the IgG2a/IgG1 ratio is higher, it is in favour of Th1 immune response that is elicited by a cell- mediated response to IFN-c[36]. IFN-c has an important role in blocking the virus spread [37]. Renegar et al. [38] showed that a vaccine formulation against Barratt (BAR) strain of influ- enza virus has significantly increased the ratio of IgG2a/IgG1 antibody titres. Also, Mahmoudi et al. investigated the immunogenicity of ISCOMs formulations loaded with a type 2 herpes simplex virus (HSV-2) antigen. Higher IgG2a antibody, IFN-c and IL-2 levels were observed in BALBc/mice immu- nized subcutaneously [39]. In another study, Madhum et al.
[40] showed a strong antibody responses and a the high fre- quency of multifunctional Th1 CD4þcells after Im immuniza- tion of BALBc/mice with ISCOM-adjuvanted influenza A H5N1 virosomal vaccine than those of non-adjuvanted vaccines . In many studies, the ability of cationic ISCOM derivations (PLUSCOMs) in antigen attachment and elicitation of T cell responses was also compared to anionic ISCOMs. It has been shown that the PLUSCOMs have advantages including the incorporation of purified anionic antigen and inducing T cell responses similar to ISCOMs [41,42].
After In or Im administration, PR8-ISC formulation had the potential to elicit more IFN-c levels compared with PR8-ISC- CIT formulation. However, it significantly decreased the ratio of IgG2a/IgG1 antibody titres. After nasal administration of these formulations, less immune responses than Im delivery was induced; especially when this formulation coated with CIT. Altogether, although after Im administration no signifi- cant difference was observed between anti-PR8 IgG titres of CIT-coated and non-coated formulations, both of these for- mulations had induced a significantly higher ratio of IgG2a/
IgG1 antibody titres to those induced with non-adjuvanted PR8 antigen (p<.001). This notable achievement showed that ISCOMATRIX adjuvanted PR8 vaccines are potent inducer of Th1 immune responses, especially after Im delivery.
473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531
532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590
Figure 3.The level of IgG1 (A), IgG2a (B) antibodies and the IgG2a/IgG1 ratio (C) of BALBc/mice immunized by In and Im routes, ten days after the last booster injection with different formulations. The assays were performed using an ELISA method in triplicate at different dilutions of serum samples. Significant differences between the PR8-ISC (Im) and PR8-ISC-CIT (Im) groups with the PR8 (Im) group marked as(p<.001). Significant differences between PR8-ISC-CIT (Im) and PR8- ISC-CIT (In) groups labelled with #(p<.05), ##(p<.01) and ###(p<.001). Data expressed as mean ± SD (n¼6).
Conclusions
It is concluded that ISCOMATRIX NPs are efficient immunoad- juvants for immunization against PR8 whole influenza virus.
This effect was proved after immunization from both nasal and Im routes. However, the chitosan coated ISCOMATRIX NPs, as cationic ISCOMATRIX adjuvant, did not show any superiority over ISCOMATRIX NPs. Chitosan-coated ISCOMATRIX NPs sowed less or comparable immune responses after In and Im administration, respectively.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
The data presented are part of Zahra Mohammadamini and Alireza Komeilinezhad Pharm. D. thesis [Grant number: 910601] supported by Vice Chancellor for Reserach, Mashhad University of Medical Sciences.
References
[1] Kaur L, Sharma A, Yadav AK, et al. Recent advances on biodegrad- able polymeric carrier-based mucosal immunization: an overview.
Artif Cells Nanomed Biotechnol. 2017;1–13.
Q1
[2] Morein B, Sundquist B, H€oglund S, et al. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature. 1984;308:457–460.
[3] Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60:915–928.
[4] Sharma S, Mukkur T, Benson HA, et al. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci. 2009;98:812–843.
[5] Homhuan A, Prakongpan S, Poomvises P, et al. Virosome and ISCOM vaccines against Newcastle disease: preparation, character- ization and immunogenicity. Eur J Pharm Sci. 2004;22:459–468.
[6] Sanders MT, Brown LE, Deliyannis G, et al. ISCOM-based vaccines:
the second decade. Immunol Cell Biol. 2005;83:119–128.
[7] Sanders MT, Deliyannis G, Pearse MJ, et al. Single dose intranasal immunization with ISCOMATRIXTM vaccines to elicit antibody- mediated clearance of influenza virus requires delivery to the lower respiratory tract. Vaccine. 2009;27:2475–2482.
[8] Coulie PG, van Snick J. Enhancement of IgG anti-carrier responses by IgG2 anti-hapten antibodies in mice. Eur J Immunol. 1985;
15:793–798.
[9] Coutelier J-P, Van der Logt J, Heessen F, et al. IgG2a restriction of murine antibodies elicited by viral infections. J Exp Med. 1987;
165:64–69.
[10] D’Souza MJ, Tawde SA, Akalkotkar A, et al. Nanotechnology in vaccine delivery. Molecular vaccines. Springer; 2014.
Q2 [11] Pearse M, Drane D. ISCOMATRIX TM adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 2004;22:
2391–2395.
[12] Sj€olander A, Cox JC, Barr IG. ISCOMs: an adjuvant with multiple functions. J Leukoc Biol. 1998;64:713–723.
[13] Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. Methods. 2006;40:53–59.
[14] Rimmelzwaan G, Baars M, Van Beek R, et al. Induction of protect- ive immunity against influenza virus in a macaque model: com- parison of conventional and iscom vaccines. J Gen Virol.
1997;78:757–765.
[15] Potter C, Jennings R. Effect of priming on subsequent response to inactivated influenza vaccine. Vaccine. 2003;21:(9):940–5.
[16] Pabreja S, Garg T, Rath G, et al. Mucosal vaccination against tuber- culosis using Ag85A-loaded immunostimulating complexes. Artif Cells Nanomed Biotechnol. 2016;44:532–539.
[17] Sambhara S, Woods S, Arpino R, et al. Heterotypic protection against influenza by immunostimulating complexes is associated with the induction of cross-reactive cytotoxic T lymphocytes.
J Infect Dis. 1998;177:1266–1274.
[18] Coulter A, Harris R, Davis R, et al. Intranasal vaccination with ISCOMATRIXVR adjuvanted influenza vaccine. Vaccine.
2003;21:946–949.
[19] G€unbeyaz M, Faraji A,Ozkul A, et al. Chitosan based delivery sys-€ tems for mucosal immunization against bovine herpesvirus 1 (BHV-1). Eur J Pharm Sci. 2010;41:531–545.
[20] Hembram KC, Prabha S, Chandra R, et al. Advances in preparation and characterization of chitosan nanoparticles for therapeutics.
Artif Cells Nanomed Biotechnol. 2016;44:305–314.
[21] Dodane V, Khan MA, Merwin JR. Effect of chitosan on epithelial permeability and structure. Int J Pharm. 1999;182:21–32.
[22] Kumar K, Dhawan N, Sharma H, et al. Bioadhesive polymers: novel tool for drug delivery. Artif Cells, Nanomed Biotechnol. 2014;
42:274–283.
[23] Wen Z-S, Xu Y-L, Zou X-T, et al. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs. 2011;
9:1038–1055.
[24] Johnson A, Chen L-M, Winne E, et al. Identification of influ- enza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs. PLoS One.
2015;10:e0128982.
[25] Liu H, Bungener L, ter Veer W, et al. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose- sparing adjuvant for pandemic influenza vaccines. Vaccine.
2011;29:2037–2043.
[26] Mehravaran A, Jaafari MR, Jalali SA, et al. The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and pro- tection against leishmaniasis in BALB/c mice. Iranian J Basic Med Sci. 2016;19:178.
[27] Amirnasr M, Sankian M, Rezaei A, et al. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46. Microb Pathog. 2016;97:38–44.
[28] Tafaghodi M, Kersten G, Jiskoot W. Nano-adjuvanted polio vac- cine: preparation and characterization of chitosan and trimethyl- chitosan (TMC) nanoparticles loaded with inactivated polio virus and coated with sodium alginate. Nanomed J. 2014;1:220–228.
[29] Jaafari MR, Badiee A, Khamesipour A, et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine.
2007;25:6107–6117.
[30] Mosafer J, Teymouri M, Abnous K, et al. Study and evaluation of nucleolin-targeted delivery of magnetic PLGA-PEG nanospheres loaded with doxorubicin to C6 glioma cells compared with low nucleolin-expressing L929 cells. Mater Sci Eng C. 2017;72:123–133.
[31] Badiee A, Jaafari MR, Khamesipour A. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Exp Parasitol. 2007;115:127–134.
[32] Sj€olander S, Drane D, Davis R, et al. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic anti- body and cytotoxic T-lymphocyte responses. Vaccine. 2001;19:
4072–4080.
[33] Helgeby A, Robson NC, Donachie AM, et al. The combined CTA1- DD/ISCOM adjuvant vector promotes priming of mucosal and sys- temic immunity to incorporated antigens by specific targeting of B cells. J Immunol. 2006;176:3697–3706.
[34] Andersen CS, Dietrich J, Agger EM, et al. The combined CTA1-DD/
ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis. Infect Immunol. 2007;75:408–416.
[35] Maruggi G, Chiarot E, Giovani C, et al. Immunogenicity and pro- tective efficacy induced by self-amplifying mRNA vaccines encod- ing bacterial antigens. Vaccine. 2017;35:361–368.
591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649
650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708
6 J. MOSAFER ET AL.
[36] Tao W, Fu T, He Z, et al. Evaluation of immunostimulatory effects of n-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride for improving live attenuated hepatitis A virus vaccine efficacy.
Viral Immunol. 2017;30:120–126.
[37] Ito R, Ozaki YA, Yoshikawa T, et al. Roles of anti-hemagglutinin IgA and IgG antibodies in different sites of the respiratory tract of vaccinated mice in preventing lethal influenza pneumonia.
Vaccine. 2003;21:2362–2371.
[38] Renegar KB, Small PA, Boykins LG, et al. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol. 2004;173:1978–1986.
[39] Mohamedi S, Brewer J, Alexander J, et al. Antibody responses, cytokine levels and protection of mice immunised with HSV-2
antigens formulated into NISV or ISCOM delivery systems.
Vaccine. 2000;18:2083–2094.
[40] Madhun AS, Haaheim LR, Nilsen MV, et al. Intramuscular Matrix-M- adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4þcells and strong antibody responses in mice. Vaccine. 2009;27:7367–7376.
[41] McBurney WT, Lendemans DG, Myschik J, et al. In vivo activity of cationic immune stimulating complexes (PLUSCOMs). Vaccine.
2008;26:4549–4556.
[42] Mehravaran A, Jaafari MR, Jalali SA, et al. Cationic immune stimu- lating complexes containing soluble leishmania antigens: prepar- ation, characterization and in vivo immune response evaluation.
Iranian J Immunol. 2015;12:274.
709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767
768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826
View publication stats View publication stats
